38I:FRA
Intellia Therapeutics Inc
€10.84
arrow_downward
-12.01%(-1.48) 1 日
4月28日, 8:13:34 GMT+2 · EUR
search
すべての記号
1 日
5 日
1 か月
6 か月
年初来
1 年
5 年
最大
| 記号 | 価格 | 変化 | 変化率 |
|---|
insights_auto38I の上位の分析情報を生成しています...
始値
€10.84
高値
€10.84
安値
€10.84
時価総額
15.40億
平均出来高
198.00
取引量
0.00
52 週高値
€24.34
52 週安値
€6.00
従業員数
377
ニュース記事
ウェブの情報から
Investing.com
·
1 時間前
Citizens raises Intellia Therapeutics stock price target on gene-editing milestone
The Clinical Trial Vanguard
·
2 時間前
Intellia Announces Proposed Public Offering of Common Stock
marketscreener.com
·
13 時間前
Intellia Therapeutics Launches $150 Million Stock Offering
プロフィール
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Intellia Therapeutics Inc について